Currently, probiotic supplementation of oncology patients is being treated very cautiously in ongoing treatment. In some cases, probiotic supplementation in a patient attenuated by treatment has caused a strong infection and required subsequent treatment or caused death. The greatest risk includes living probiotic bacteria that, in rare cases, may cause sepsis in a weakened patient. As a result, physicians maintain caution and distance from using probiotic cultures to deal with diarrheal diseases during ongoing chemotherapy or radiotherapy.
Our approach allows probiotic supplementation of oncology patients in a completely safe form with no risk of life threatening sepsis. The main advantage is the possibility of live probiotic processing by dry lysis technology which we developed, where the cells of probiotic bacteria after lyophilization are disrupted and decomposed in
a careful and controlled manner. Thus, a number of active components are released from the cells, which have a very positive effect on the mucosal immunity and the overall regeneration of the intestinal mucosa. At the same time, the components released from lysed probiotic bacteria specifically inhibit the potential microbial
origin of diarrhea. Our technology represents a unique process of so-called Dry lysis, which allows us to safely disturb probiotic bacteria without thermal denaturation during the process. This makes it unique to preserve the biological activity of the active molecules obtained from probiotic bacteria. Molecules released from disrupted probiotic bacteria then act to restore the intestinal mucosa and supression of pathogenic bacteria propagation by a number of molecules. Probiotic lysates, which will retain the native structure of the individual components thus obtained, can absolutely fulfill the same function as the live bacteria. On the contrary, due to the release of biologically active molecules, they can act better in the short term than live bacteria.
The newly developed ONCOTICS product will allow long-term and safe supplementation of oncology patients during treatment. We will reduce the risk of diarrhea development or reduce the intensity of this side effect of existing oncology treatment. We will relieve patients of disturbing frustrating conditions when they have to spend a part of the therapy by permanent stress from diarrhea, dehydration, and exhaustion. Any limitation of these conditions has two baselines of help:
· The humane level: reduction of pain, exhaustion and psychological harm due to undesirable effects of treatment.
· Economical savings: any limitation or reduction of side effects will normally lead to lower costs spent on treating these side effects.
